Corvus Pharmaceuticals, Inc. (CRVS)
10.17
-0.43
(-4.06%)
USD |
NASDAQ |
Nov 17, 16:00
10.50
+0.33
(+3.24%)
After-Hours: 20:00
Corvus Pharmaceuticals Enterprise Value : 655.21M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 655.21M |
| November 16, 2026 | 691.47M |
| November 13, 2026 | 694.84M |
| November 12, 2026 | 693.16M |
| November 11, 2026 | 764.83M |
| November 10, 2026 | 756.40M |
| November 09, 2026 | 754.71M |
| November 06, 2026 | 686.41M |
| November 05, 2026 | 618.11M |
| November 04, 2026 | 688.94M |
| November 03, 2026 | 626.55M |
| November 02, 2026 | 615.58M |
| October 30, 2026 | 643.41M |
| October 29, 2026 | 660.27M |
| October 28, 2026 | 684.73M |
| October 27, 2026 | 686.41M |
| October 26, 2026 | 678.82M |
| October 23, 2026 | 685.57M |
| October 22, 2026 | 695.69M |
| October 21, 2026 | 645.10M |
| October 20, 2026 | 660.27M |
| October 19, 2026 | 611.37M |
| October 16, 2026 | 600.41M |
| October 15, 2026 | 628.23M |
| October 14, 2026 | 588.60M |
| Date | Value |
|---|---|
| October 13, 2026 | 591.13M |
| October 12, 2026 | 645.10M |
| October 09, 2026 | 684.73M |
| October 08, 2026 | 658.59M |
| October 07, 2026 | 675.45M |
| October 06, 2026 | 688.10M |
| October 05, 2026 | 703.28M |
| October 02, 2026 | 716.77M |
| October 01, 2026 | 719.30M |
| September 30, 2026 | 769.05M |
| September 29, 2026 | 774.76M |
| September 28, 2026 | 784.02M |
| September 25, 2026 | 762.98M |
| September 24, 2026 | 778.13M |
| September 23, 2026 | 840.38M |
| September 22, 2026 | 916.08M |
| September 21, 2026 | 830.28M |
| September 18, 2026 | 842.06M |
| September 17, 2026 | 841.22M |
| September 16, 2026 | 814.30M |
| September 15, 2026 | 874.87M |
| September 14, 2026 | 888.32M |
| September 11, 2026 | 871.50M |
| September 10, 2026 | 874.02M |
| September 09, 2026 | 906.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arcturus Therapeutics Holdings, Inc. | 63.88M |
| CytomX Therapeutics, Inc. | 78.32M |
| ACADIA Pharmaceuticals, Inc. | 2.261B |
| Alnylam Pharmaceuticals, Inc. | 20.36B |
| Anika Therapeutics, Inc. | 153.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.34M |
| Total Expenses (Quarterly) | 20.34M |
| EPS Diluted (Quarterly) | -0.22 |
| Earnings Yield | -7.03% |
| Normalized Earnings Yield | -7.030 |